History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses

Le Dran, 1742 Trnka, 1783 Hoption Cann, 2002, Spontaneous regression: a hidden treasure buried in time, Med. Hypotheses, 58, 115, 10.1054/mehy.2001.1469 Coley, 1910, The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus), Proc. Roy. Soc. Med., 3, 1, 10.1177/003591571000301601 Richardson, 1999, Coley toxins immunotherapy: a retrospective review, Alternative Ther. Health Med., 5, 42 Dock, 1904, The influence of complicating diseases upon leukemia, Am. J. Med. Sci., 127, 563, 10.1097/00000441-190412740-00001 Bierman, 1953, Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia, Cancer, 6, 591, 10.1002/1097-0142(195305)6:3<591::AID-CNCR2820060317>3.0.CO;2-M Pasquinucci, 1971, Possible effect of measles on leukaemia, Lancet, 1, 136, 10.1016/S0140-6736(71)90869-5 Gross, 1971, Measles and leukaemia, Lancet, 1, 397, 10.1016/S0140-6736(71)92232-X Zygiert, 1971, Hodgkin's disease: remissions after measles, Lancet, 1, 593, 10.1016/S0140-6736(71)91186-X Taqi, 1981, Regression of Hodgkin's disease after measles, Lancet, 1, 1112, 10.1016/S0140-6736(81)92286-8 Bluming, 1971, Regression of Burkitt's lymphoma in association with measles infection, Lancet, 2, 105, 10.1016/S0140-6736(71)92086-1 De Pace, 1912, Sulla scomparsa di un enorme cancro vegetante del collo dell'utero senza cura chirur-gica, Ginecologia, 9, 82 Kalantzis, 2006, Constantin Levaditi (1874-1953): a pioneer in immunology and virology, J. Med. Biogr., 14, 178, 10.1258/j.jmb.2006.05-30 Enders, 1949, Cultivation of the lansing strain of poliomyelitis virus in cultures of various human embryonic tissues, Science, 109, 85, 10.1126/science.109.2822.85 Masters, 2002, HeLa cells 50 years on: the good, the bad and the ugly, Nat. Rev. Cancer, 2, 315, 10.1038/nrc775 Turner, 2012, Development of the polio vaccine: a historical perspective of Tuskegee University's role in mass production and distribution of HeLa cells, J. Health Care Poor Underserved, 23, 5, 10.1353/hpu.2012.0151 Hoster, 1949, Studies in Hodgkin's syndrome; the association of viral hepatitis and Hodgkin's disease; a preliminary report, Cancer Res., 9, 473 Southam, 1952, Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus, Cancer, 5, 1025, 10.1002/1097-0142(195209)5:5<1025::AID-CNCR2820050518>3.0.CO;2-Q Huebner, 1956, Studies on the use of viruses in the treatment of carcinoma of the cervix, Cancer, 9, 1211, 10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7 Asada, 1974, Treatment of human cancer with mumps virus, Cancer, 34, 1907, 10.1002/1097-0142(197412)34:6<1907::AID-CNCR2820340609>3.0.CO;2-4 Alberts, 2018, The advent of oncolytic virotherapy in oncology: the Rigvir® story, Eur. J. Pharmacol., 837, 117, 10.1016/j.ejphar.2018.08.042 Martuza, 1991, Experimental therapy of human glioma by means of a genetically engineered virus mutant, Science, 10, 854, 10.1126/science.1851332 Barker, 1987, Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection, Virology, 156, 107, 10.1016/0042-6822(87)90441-7 Larson, 2015, Going viral: a review of replication-selective oncolytic adenoviruses, Oncotarget, 6, 19976, 10.18632/oncotarget.5116 Goradel, 2021, Oncolytic virotherapy: challenges and solutions, Curr. Probl. Cancer, 45, 10.1016/j.currproblcancer.2020.100639 Cook, 2020, Clinical application of oncolytic viruses: a systematic review, Int. J. Mol. Sci., 21, 7505, 10.3390/ijms21207505 Andtbacka, 2019, Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma, J Immunother Cancer, 6, 145, 10.1186/s40425-019-0623-z Kaufman, 2022, Talimogene laherparepvec: moving from first-in-class to best-in-class, Front. Mol. Biosci., 9, 10.3389/fmolb.2022.834841 Otani, 2022, Implications of immune cells in oncolytic herpes simplex virotherapy for glioma, Brain Tumor Pathol., 39, 57, 10.1007/s10014-022-00431-8 Di Somma, 2019, The oncolytic virus dl922-947 triggers immunogenic cell death in mesothelioma and reduces xenograft growth, Front. Oncol., 9, 564, 10.3389/fonc.2019.00564 Malfitano, 2019, Virotherapy as a potential therapeutic approach for the treatment of aggressive thyroid cancer, Cancers, 11, 1532, 10.3390/cancers11101532 Iannuzzi, 2020, Pharmacological inhibition of WEE1 potentiates the antitumoral effect of the dl922-947 oncolytic virus in malignant mesothelioma cell lines, Int. J. Mol. Sci., 21, 7333, 10.3390/ijms21197333 Malfitano, 2020, From single agents to combinatorial treatments, Biochem. Pharmacol., 177, 10.1016/j.bcp.2020.113986 Prestwich, 2008, Immunotherapeutic potential of oncolytic virotherapy, Lancet Oncol., 9, 610, 10.1016/S1470-2045(08)70163-3 van Vloten, 2018, Critical interactions between immunogenic cancer cell death, oncolytic viruses, and the immune system define the rational design of combination immunotherapies, J. Immunol., 15, 450, 10.4049/jimmunol.1701021 Senzer, 2009, Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma, J. Clin. Oncol., 27, 5763, 10.1200/JCO.2009.24.3675 Zamarin, 2014, Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer, Mol Ther Oncolytics, 10 Ribas, 2017, Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy, Cell, 7, 1109, 10.1016/j.cell.2017.08.027